U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 22,041 shares of the medical research company’s stock after acquiring an additional 256 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in Amgen were worth $7,102,000 as of its most recent filing with the SEC.
Other institutional investors have also made changes to their positions in the company. Hoxton Planning & Management LLC lifted its position in shares of Amgen by 5.7% during the 1st quarter. Hoxton Planning & Management LLC now owns 739 shares of the medical research company’s stock worth $210,000 after buying an additional 40 shares during the period. First Financial Corp IN boosted its stake in shares of Amgen by 15.7% in the 1st quarter. First Financial Corp IN now owns 390 shares of the medical research company’s stock valued at $111,000 after purchasing an additional 53 shares in the last quarter. Sound Income Strategies LLC grew its holdings in shares of Amgen by 17.4% in the 1st quarter. Sound Income Strategies LLC now owns 1,080 shares of the medical research company’s stock worth $307,000 after purchasing an additional 160 shares during the last quarter. Elevated Capital Advisors LLC grew its stake in Amgen by 8.0% during the first quarter. Elevated Capital Advisors LLC now owns 1,328 shares of the medical research company’s stock worth $378,000 after buying an additional 98 shares during the last quarter. Finally, Sovereign Financial Group Inc. increased its holdings in shares of Amgen by 11.0% during the first quarter. Sovereign Financial Group Inc. now owns 1,451 shares of the medical research company’s stock worth $413,000 after buying an additional 144 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.
Amgen Trading Down 1.4 %
AMGN traded down $4.51 during midday trading on Wednesday, reaching $315.15. 376,036 shares of the company were exchanged, compared to its average volume of 2,431,741. The stock has a market capitalization of $169.06 billion, a P/E ratio of 45.67, a PEG ratio of 2.86 and a beta of 0.61. Amgen Inc. has a one year low of $249.70 and a one year high of $346.85. The stock’s 50-day simple moving average is $325.93 and its 200 day simple moving average is $313.11. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26.
Amgen Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio is currently 128.57%.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. Morgan Stanley lowered their target price on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Dbs Bank raised Amgen to a “strong-buy” rating in a report on Monday, September 16th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price objective (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Finally, Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $332.55.
Check Out Our Latest Stock Analysis on Amgen
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
- Five stocks we like better than Amgen
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- High Flyers: 3 Natural Gas Stocks for March 2022
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.